Molecular dynamics, dynamic site mapping, and highthroughput virtual screening on leptin and the Ob receptor as anti-obesity target

AbstractBody weight control is a mechanism finely regulated by several hormonal, metabolic, and nervous pathways. The leptin receptor (Ob-R) is crucial for energy homeostasis and regulation of food uptake. Leptin is a 16 kDa hormone that is mainly secreted by fat cells into the bloodstream, and under normal circumstances, circulating levels are proportionate to the fat body mass. Sensing of elevated leptin levels by the hypothalamic neurocircutry activates a negative feedback loop resulting in reduced food intake and increased energy expenditure. Decreased concentrations lead to opposite effects. Therefore rational design of leptin agonists constitute an appealing challenge in the battle against obesity. In this study, we performed protein-protein docking among the re-built crystal structure of leptin and leptin binding domain (LBD). The obtained complex was used as a starting point to carry out nanosecond-scale molecular dynamics simulations to characterize the key regions in terms of physical-chemical features involved in the protein-protein interaction (dynamic site mapping filtered by means multivariate analysis) and used to carry out a HTVS. The main goal of this study was to suggest guidelines for the rational drug design of new agonists of leptin. Identified hits could be a consistent starting point to carry out in vitro testing. FigureLeptin and the Ob receptor

[1]  Anna Maria Almerico,et al.  Combined Use of PCA and QSAR/QSPR to Predict the Drugs Mechanism of Action. An Application to the NCI ACAM Database , 2009 .

[2]  Michele Magrane,et al.  UniProt Knowledgebase: a hub of integrated protein data , 2011, Database J. Biol. Databases Curation.

[3]  J. Tavernier,et al.  Selection of non-competitive leptin antagonists using a random nanobody-based approach. , 2012, The Biochemical journal.

[4]  A. Lauria,et al.  Lead optimization through VLAK protocol: new annelated pyrrolo-pyrimidine derivatives as antitumor agents. , 2012, European journal of medicinal chemistry.

[5]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[6]  Rene Devos,et al.  Identification and expression cloning of a leptin receptor, OB-R , 1995, Cell.

[7]  A. M. Almerico,et al.  Virtual lock-and-key approach: the in silico revival of Fischer model by means of molecular descriptors. , 2011, European journal of medicinal chemistry.

[8]  Anna Maria Almerico,et al.  Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors , 2009, Comput. Biol. Chem..

[9]  Ruben Abagyan,et al.  Recipes for the Selection of Experimental Protein Conformations for Virtual Screening , 2010, J. Chem. Inf. Model..

[10]  J. Tavernier,et al.  Leptin Receptor Activation Depends on Critical Cysteine Residues in Its Fibronectin Type III Subdomains* , 2005, Journal of Biological Chemistry.

[11]  Anna Maria Almerico,et al.  Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis , 2008, J. Comput. Aided Mol. Des..

[12]  Marco Biasini,et al.  Toward the estimation of the absolute quality of individual protein structure models , 2010, Bioinform..

[13]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[14]  José N. Onuchic,et al.  The Unique Cysteine Knot Regulates the Pleotropic Hormone Leptin , 2012, PloS one.

[15]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[16]  Pascal Benkert,et al.  QMEAN server for protein model quality estimation , 2009, Nucleic Acids Res..

[17]  M. Tutone,et al.  Multivariate analysis in the identification of biological targets for designed molecular structures: the BIOTA protocol. , 2014, European journal of medicinal chemistry.

[18]  J. Tavernier,et al.  Mapping of the interface between leptin and the leptin receptor CRH2 domain , 2005, Journal of Cell Science.

[19]  Markus Wagener,et al.  A flexible approach to induced fit docking. , 2007, Journal of medicinal chemistry.

[20]  Orly Dym,et al.  Subcloning, Expression, Purification, and Characterization of Recombinant Human Leptin-binding Domain* , 2002, The Journal of Biological Chemistry.

[21]  J. Tavernier,et al.  Mapping of the Leptin Binding Sites and Design of a Leptin Antagonist* , 2004, Journal of Biological Chemistry.

[22]  Peter J. Artymiuk,et al.  Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody. , 2012, Structure.

[23]  Christopher R. Corbeil,et al.  Docking Ligands into Flexible and Solvated Macromolecules, 1. Development and Validation of FITTED 1.0 , 2007, J. Chem. Inf. Model..

[24]  Woody Sherman,et al.  Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering , 2012, Chemical biology & drug design.

[25]  In-silico screening of new potential Bcl-2/Bcl-xl inhibitors as apoptosis modulators , 2009, Journal of molecular modeling.

[26]  In vitro and in silico studies of polycondensed diazine systems as anti-parasitic agents. , 2012, Bioorganic & medicinal chemistry letters.

[27]  Anna Maria Almerico,et al.  Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti- obesity lead compounds. , 2014, Current pharmaceutical design.

[28]  P. J. Jones,et al.  A role for dietary fat in leptin receptor, OB-Rb, function. , 2001, Life sciences.

[29]  Anne-Sophie de Smet,et al.  Mapping of Binding Site III in the Leptin Receptor and Modeling of a Hexameric Leptin·Leptin Receptor Complex* , 2006, Journal of Biological Chemistry.

[30]  Ruben Abagyan,et al.  Consistent Improvement of Cross-Docking Results Using Binding Site Ensembles Generated with Elastic Network Normal Modes , 2009, J. Chem. Inf. Model..

[31]  A. M. Almerico,et al.  Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors , 2012, Journal of Molecular Modeling.

[32]  G. Frühbeck.  A heliocentric view of leptin , 2001, Proceedings of the Nutrition Society.

[33]  Anna Maria Almerico,et al.  Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence. , 2012, Biochemical and biophysical research communications.

[34]  H. Toh,et al.  Homology modeling of human leptin/leptin receptor complex. , 2000, Biochemical and biophysical research communications.

[35]  A. M. Almerico,et al.  A3 adenosine receptor: homology modeling and 3D-QSAR studies. , 2013, Journal of molecular graphics & modelling.

[36]  J. M. Beals,et al.  Crystal structure of the obese protein Ieptin-E100 , 1997, Nature.

[37]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[38]  Pascal Benkert,et al.  QMEAN: A comprehensive scoring function for model quality assessment , 2008, Proteins.

[39]  A. Lauria,et al.  New annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with potent anticancer activity, designed through VLAK protocol. , 2013, European journal of medicinal chemistry.

[40]  Ilya A Vakser,et al.  Development and testing of an automated approach to protein docking , 2005, Proteins.

[41]  M. Tota,et al.  Localization of leptin binding domain in the leptin receptor. , 1998, Molecular pharmacology.

[42]  Yang Zhang,et al.  I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.